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Introduction 1 
Primary orbital melanoma accounts for less than 1% of all primary orbital 2 
neoplasms.1 In the largest clinico-pathological series on this subject to date, all 21 3 
cases occurred in Caucasian patients, with a mean age at diagnosis of 42 years. Of 4 
these cases, 19 (90%) were associated with an orbital blue naevus. Of these 19 5 
cases; 10 cases also showed some form of congenital melanosis (naevus of Ota or 6 
ocular melanocytosis).2 Death from metastatic tumour occurred in 38% of cases, 7 
after a mean of 4.5 years follow up, with liver (88%) and brain (12%) being main 8 
targets of metastases.2 A recent clinical study of 13 cases showed mortality from the 9 
disease in 5/13 cases with a mean survival of 44 months.3 We present our 10 
experience of the clinical, histological and genetic profile from 6 cases of primary 11 
orbital melanoma and compare this with what is already known about uveal, 12 
cutaneous, and conjunctival melanomas. 13 
Methods 14 
This was a retrospective study performed on archival paraffin tissue surplus to 15 
diagnosis, held in the Histopathology Department, Royal Hallamshire Hospital 16 
Sheffield. All patients underwent standard written consent for the exenteration and 17 
incisional biopsy surgical procedures.  Institutional Review Board/ Ethics Committee 18 
approval was obtained (The study was approved nationally (15/NW/0239) and by the 19 
Sheffield Teaching Hospitals Research & Development Office, under study number 20 
STH 19478, sub-study to STH 15427) for the use of anonymised retrospective 21 
formalin-fixed paraffin tissue, according to the UK Human Tissue Act (HTA) 22 
guidelines that governs the research use of such material that is surplus to 23 
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diagnosis. The research adhered to the tenets of the Declaration of Helsinki. The 24 
study was funded by the Sheffield Ocular Oncology Fund. 25 
The clinical presentation / course and radiological features of patients were obtained 26 
from clinical records held in the Medical Records Department and from the 27 
Radiology Departments of the Royal Hallamshire Hospital Sheffield UK respectively. 28 
All histopathology data was obtained from slides and results held in the National 29 
Specialist Ophthalmic Pathology Service (NSOPS) archive, in the Department of 30 
Histopathology at the same hospital.  31 
Inclusion Criteria for study 32 
The inclusion criteria for the study were the presence of a primary orbital melanoma, 33 
with no clinical /radiological/imaging or other investigative modality evidence of 34 
intraocular, conjunctival, skin (including eyelid), mucosal (non-conjunctival) 35 
melanoma.  36 
Tissue fixation and Immunohistochemistry  37 
All surgically sampled tissue was fixed in standard 10% buffered formalin and 38 
exposed to standard processing to paraffin wax. 4 micron sections were cut and 39 
stained with haematoxylin and eosin (H&E). All cases were exposed to BAP-1, 40 
Melan A, HMB45 and Sox-10 immunohistochemistry. BAP1 retrieval of antigen was 41 
with pH8 (high pH) Dako retrieval solution. BAP1 antibody (Santa Cruz, California, 42 
Clone–C4; SC28383) was used at a dilution of 1:400 for 50 minutes, followed by a 43 
mouse link amplification step for 10 minutes, the Dako Flex Envision system HRP 44 
step for 20 minutes and finally DAB for 5 minutes. Melan A-Retrieval of antigen was 45 
with Agilent High pH EnV FLEX target retrieval solution. Melan A antibody (Agilent 46 
USA Clone A103) was used as a ready to use solution for 20 minutes, followed by 47 
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Agilent EnV FLEX HRP for 20 minutes and DAB for 5 minutes. HMB45- Retrieval of 48 
antigen was with Agilent High pH EnV FLEX target retrieval solution. HMB45 49 
antibody (Agilent USA, Clone HMB45) was used as a ready to use solution for 20 50 
minutes, followed by mouse link amplification step for 10 minutes and then Agilent 51 
EnV FLEX HRP for 20 minutes and DAB for 5 minutes. Sox10- Heat induced epitope 52 
retrieval was performed using Leica Bond Epitope Retrieval Solution for 2 minutes at 53 
99oC (high pH, Leica, AR9640). Peroxide block was applied for 5 minutes (as per 54 
detection kit) followed by application of SOX10 (CellMarque rabbit monoclonal 55 
EP268, diluted 1/200, cat. no. 385R-15) for 15 minutes. The Leica Bond III 56 
immunostaining platform was used, with Leica Bond Polymer Refine Detection with a 57 
DAB chromogen (Leica, DS9800).  58 
 59 
DNA extraction, array comparative genomic hybridisation (array CGH), PCR 60 
and Sanger sequencing  61 
DNA from 6 cases of primary orbital melanomas was extracted from formalin-fixed 62 
paraffin-embedded tumour material as previously described.4 Array comparative 63 
genomic hybridization (aCGH) was performed on all 6 cases as detailed previously.4 64 
Sequencing for mutations of GNAQ, GNA11 and BRAF was performed as detailed 65 
previously.5, 6 Amplification of NRAS, SF3B1 and EIF1AX regions was performed by 66 
standard PCR. PCR reagent concentrations were 1.5 mM MgCl2, 10 pmol/l primers 67 
and 12.5 mM dNTPs. 7-9 Due to the TERT promoter region being G-C rich, the 68 
protocol was adapted using a GC rich PCR system (Roche, Basel, Switzerland).10 69 
PCR conditions were 0.5 M MgCl2, 30 pmol/l primers and 12.5 mM dNTPs. PCR 70 
product size was verified by agarose gel electrophoresis. Table 1 summarises the 71 
primers used. Following amplification, PCR products were purified to remove PCR 72 
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reagents using a QIAquick PCR Purification Kit (Qiagen, Hilden, Germany). 73 
Sequencing reactions were performed using a BigDye Terminator V.3.0 Cycle 74 
Sequencing Ready Reaction Kit (Life Technologies, Carlsbad, USA). Sequencing 75 
traces were analysed using FinchTV software (Geospisa Seattle, USA).  76 
Results 77 
Clinical and Radiological findings 78 
Table 2 summarises the clinical and radiological features of the 6 cases. All patients 79 
were Caucasian and comprised 4 males (age range 65 to 91 years) and 2 females 80 
(26 and 65 years), with a male to female ratio of 3:1. The mean age at diagnosis was 81 
66 years (range 26-91 years). The mean follow-up after histological diagnosis was 82 
39 months (range 6 weeks to 84 months). Proptosis was common at presentation, 83 
and one case (case 1) showed episcleral and scleral pigmentation, without eyelid 84 
skin changes, indicative of ocular melanocytosis. None of the cases had clinical 85 
evidence of conjunctival, uveal, eyelid skin or systemic melanoma. Radiologically, 86 
what was particularly striking was the proximity of the melanomas to extraocular 87 
muscles, either located adjacent to the insertion or the body of the muscles or focally 88 
invading the muscle. No cases showed extension of the orbital mass beyond the 89 
bony orbit. Case 4 showed concurrent metastatic disease in the liver and bones.  90 
Histopathology findings (see Figure 1) 91 
These are summarised in Table 3. Most tumours comprised a variable mixture of 92 
spindle and epithelioid melanoma cells that were positive for melanocytic markers 93 
Melan A, HMB45 and Sox10. 2/6 cases had balloon cell change. 1/6 cases showed 94 
histological confirmation of ocular melanocytosis (case 1) and in a further 2 cases, 95 
benign spindle melanocytes were present around and beyond the orbital melanomas 96 
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(case 2 and 3). Balloon cell changes were seen in cases 4 and 6 but not in the other 97 
cases. 98 
Array CGH for Chromosomal copy number changes (See Figure 2) 99 
Array CGH data was analysed using Agilent Genomic Workbench Software v.6.0 100 
(Agilent Technologies) and Nexus Copy Number Software v8.0 (BiodiscoveryH). 101 
Findings using both software’s were comparable and revealed targeting of individual 102 
chromosomes rather than widespread genomic imbalance. The results for each 103 
tumour are presented in Table 4. The chromosomal copy number changes are 104 
summarised in Fig 2. The most frequent gains were of 6p (5/6), 8q (4/6), 17q (4/6), 105 
6q (2/6), and 20p (2/6). The most frequently lost regions were 1p (2/6), 9p (2/6), 16q 106 
(2/6), 17p (2/6). 107 
Mutational Analysis 108 
Mutational profiling of genes commonly mutated in melanoma was performed using 109 
standard PCR and Sanger sequencing. The genes and mutational hotspots analysed 110 
are described in Table 4. Based on mutational data there is a suggestion of 2 distinct 111 
subgroups emerging in orbital melanomas. Those that exhibit mutations in GNAQ, 112 
GNA11 or SF3B1 (cases 1, 2 and 3) and those that contain mutations in TERTp and 113 
NRAS (cases 5 and 6). Case 4 did not exhibit mutations in any of the sites analysed, 114 
however it is worth noting that data for EIF1AX and TERTp mutations was not 115 
available due to poor quality DNA extracted from this sample. Cases 1 and 3 116 
contained different missense substitutions at codon 625 of SF3B1 (case 1 exhibiting 117 
a missense substitution of C>G and case 3 exhibiting a C>T substitution). Both 118 
mutations of SF3B1 (R625G and R625C) have previously been reported to be 119 
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present in primary UM. 11-13 Case 1 also exhibited an R183Q mutation in exon 4 of 120 
GNAQ. This is an interesting observation as a mutation at this site is much rarer 121 
compared to the Q209 site (2.8% versus 44.8% in primary UM). 6 Case 2 exhibited a 122 
Q209L missense substitution of A>T at codon 209 of GNA11, a mutation seen in 123 
approximately 40-50% of UM cases.6, 14-16 Cases 5 and 6 both exhibited mutations in 124 
the genes NRAS and TERTp (table 3). Both cases harboured a G12V missense 125 
substitution of G>T in codon 12 of NRAS and a C250T missense substitution of C>T 126 
in the promoter region of TERT. 127 
 128 
Discussion 129 
This study has documented the clinical, histological and molecular genetic findings 130 
for 6 cases of primary orbital melanoma. The clinical and histological findings concur 131 
with a previous study by Tellado et al 2, who documented 21 cases of primary orbital 132 
melanoma, which showed that the histology of orbital melanoma was very similar to 133 
UM. The melanoma cell types presented here comprised a variable mix of spindle 134 
and epithelioid cells and in some cases, extracellular matrix networks seen, as in 135 
UM. The primary orbital melanomas had a striking tendency to occur next to or within 136 
extraocular muscles. Most cases of primary orbital melanoma are thought to arise 137 
from orbital benign melanocytes or blue nevi, within or without the setting of 138 
oculo(dermal) melanocytosis.2 These benign melanocytes tend to distribute along 139 
orbital fascial planes or within extraocular muscle, which would explain why in 5/6 140 
cases, the melanomas were located as they were.   141 
Case 1 featured ocular melanocytosis and showed a genetic profile identical to UM 142 
(monosomy 3 (M3) and gain of 8q), with loss of BAP1 protein nuclear expression 143 
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and featured liver metastases. As Changes of M3, 8q+ and loss of BAP1 protein 144 
nuclear expression, have all been significantly correlated with the development of 145 
hepatic metastases in UM, the observation of liver metastases in case 1 is perhaps 146 
not unduly surprising.  This could represent a misclassified case of UM with 147 
secondary spread to the orbit from the ipsilateral or contralateral uvea. However, the 148 
benefit of exenteration histological examination showed no evidence of active or 149 
regressed lesions of UM in the uvea making it highly unlikely that it represented a 150 
UM. Similarly, none of the remaining exenterated cases showed evidence of uveal or 151 
conjunctival pathology, confirming that the orbital melanomas were indeed primary 152 
tumours.  Interestingly, case 1 also showed a mutation in SF3B1, which, in the 153 
context of UM, is rarely reported in conjunction with loss of BAP1 expression. 11 154 
Case 1  also contained a rare mutation of GNAQ, not often observed in UM. 6  155 
There is a wealth of data on the genetic alterations of UM 17-21, with less known 156 
about conjunctival melanomas 22-24, and there are no reports about the mutational 157 
and global chromosomal analysis of primary orbital melanomas. The findings of this 158 
investigation confirm that primary orbital melanomas share similarities with other 159 
forms of melanoma. The most common change (6p+), found in 5/6 primary orbital 160 
melanomas, is consistently reported for cutaneous, UM (including iris) and 161 
conjunctival melanoma.21, 24-29 Other alterations, although less frequent (1p- and 162 
8q+), are also reported across the spectrum of melanoma.22  In contrast M3 found in 163 
one case is characteristic of UM, whilst other changes such as 17q+ are rarely 164 
observed in UM but have been reported for conjunctival melanoma.20-22, 25, 26 165 
Likewise, mutations of TERTp occur in conjunctiva melanoma but not UM, and 166 
GNA11 and SF3B1 are associated with UM but not conjunctival melanoma.6, 13, 22, 23  167 
When the cases are separated on the basis of mutational profile in combination with 168 
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genetic imbalances, it is apparent that cases 1, 2 and 3 are more akin to UM (M3 169 
and 8q+ with GNAQ, GNA11 and SF3B1 mutations), whilst cases 4, 5 and 6 have 170 
mutations of NRAS 12 and TERTp and chromosomal imbalances similar to those of 171 
conjunctival melanoma.  Iris melanomas equally have been reported to have a mixed 172 
genotype, sharing mutations of both cutaneous (BRAF/ NRAS) and posterior UM 173 
(GNAQ/ GNA11 and SF3B1), 29 but the segregation on the basis of mutations is not 174 
as distinct as seen here for the orbital melanomas.  It is also remarkable that two of 175 
the cases (Case 5 and 6) have very distinctive profiles, both having 16q-, evidence 176 
of i(17q) and a tight focal amplification of 20p, findings which, although similar to 177 
conjunctival melanoma 22, may suggest that primary orbital melanomas have their 178 
own characteristic changes. To exclude cross contamination, the analysis was 179 
repeated and confirmed the similarity of the genetic changes in these two cases.  180 
It is important to also consider the locality of these primary orbital melanomas. 181 
Posterior UM, in particular those affecting the ciliary body, are more likely to have 182 
M3.17-20 In this study Case 1, with both M3 and loss of BAP1 nuclear expression, 183 
was located in the posterior orbit towards the apex. In contrast cases 5 and 6 had 184 
relatively anterior locations compared to the other cases, and both had the anterior 185 
aspect of the tumour biopsied which abutted the conjunctiva. For these orbital 186 
melanomas, the mutational signature of NRAS and TERTp is shared with 187 
conjunctival and skin melanoma.22, 23 It is tempting to speculate whether proximity of 188 
the primary orbital melanoma to the conjunctiva, or anterior orbit, imparts a 189 
conjunctiva-type genetic signature, possibly mediated via light exposure; compared 190 
to the posteriorly located orbital melanomas, which would be relatively unexposed to 191 
light and more UM-like in their genetic profile. This possibility could only be tested by 192 
mapping different parts of a primary orbital melanoma to assess whether it was 193 
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made up of a mixture of conjunctival melanoma-like and UM-like genetic signatures.  194 
On this point however, it is worth noting that all of the 3 cases with a more UM-like 195 
genetic signature (cases 1, 2 and 3) showed a benign precursor lesion whereas the 196 
other 3 cases did not; although 2 of these latter cases were biopsies which did not 197 
sample the background non-tumour tissue. In the remaining case, the melanoma did 198 
not show a benign background precursor. This may indicate a genuine absence of a 199 
precursor or effacement of a precursor lesion by the melanoma. Ocular 200 
melanocytosis is a risk factor for UM but not conjunctival melanoma.30 Although 201 
speculative, the presence of a benign precursor lesion may be a surrogate marker of 202 
one of the two genetic subgroups for primary orbital melanoma suggested by the 203 
study.  204 
Genetic changes are powerful prognostic biomarkers for UM, but far less so for 205 
conjunctival melanoma.  Poor prognosis for UM can be assigned by the presence of 206 
M3, 8q+ and 1p-, whilst 6p+ is usually associated with a better outcome and 207 
mutations of SF3B1 and BAP1 loss also associate with metastasis.15, 17, 18, 20 Given 208 
these associations Case 1 has all the classic features of a poor prognosis UM (1p-, 209 
M3 8q+, and absent BAP1 nuclear staining), and it is not perhaps surprising under 210 
these circumstances that the patient died from associated hepatic metastases.  The 211 
other 2 cases with a more UM-like profile (2 and 3), had no metastases at the point 212 
of study, but did have some characteristic indicators of poor prognosis; including 213 
those that may predispose to metastasis over a longer period.7, 13, 20, 25, 31, 32 214 
Extended observation may clarify the association. For cases 4, 5 and 6, there was 215 
no consistent biomarker that related to the development of metastasis, and just as 216 
with conjunctival melanoma, further biomarkers would be advantageous.  A recent 217 
study found mutations present in the SF3B1 gene in 4/12 orbital melanomas and 218 
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suggests these mutations are associated with a better outcome in this tumour type.  219 
However, this study was limited to analysis of chromosomes 1, 3, 6 and 8 and 220 
therefore correlations to a non-UM profile could not be made from this series. 33   221 
 222 
In summary, we have presented the genetic profiles of 6 cases of primary orbital 223 
melanoma, which suggests that there may be two potential genetic groups, one of 224 
which may associate with melanocytosis / benign precursors. However, the study is 225 
limited by the analysis of 6 cases. Studying a larger cohort of cases will hopefully 226 
allow a prognostic stratification based on clinical, histological and molecular features, 227 
similar to current prognostic strategies for UM.34 Secondly, patients with ocular 228 
melanocytosis who develop proptosis should be imaged urgently to rule out primary 229 
orbital melanoma. 230 
 231 
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Figure 1 Histology images and immunohistochemistry findings.  237 
A-Haematoxylin and Eosin (H&E) stained section showing a spindle cell rich area of 238 
primary orbital melanoma (Case 1). 239 
B- An epithelioid cell rich area (Case 2). 240 
C-Focal clear cell changes seen in cases 4 and 6. 241 
D-The melanoma (bottom) abutting extraocular muscle (top). 242 
E- Sox 10 nuclear positivity of primary orbital melanoma. 243 
F-Background benign pigmented melanocytes present in background orbital soft 244 
tissue around and beyond some cases of primary orbital melanoma (Case 2).  245 
G-Case 1: immunohistochemistry with BAP1, showing absent nuclear staining and 246 
some staining of the cytoplasm (Case 1). 247 
H-Case 2: immunohistochemistry with BAP1, showing nuclear staining (Cases 2 to 6 248 
showed this pattern of staining).  249 
 250 
Figure 2 Array CGH profiles form 6 orbital melanomas, segregated on the 251 
basis of mutational signatures and copy number aberrations. 252 
The cases were broadly divided into those melanomas that had mutations common 253 
to UM and those with mutations more frequent amongst conjunctival and cutaneous 254 
melanoma.  Cases 1, 2 and 3, either had a GNAQ, GNA11 or a SF3B1 mutation and 255 
/ or chromosome alterations commonly associated with UM such as M3 and 8q+ 256 
(often specifically in the form of an i(8q) as likely in case 3).  Cases 4, 5 and 6, had 257 
mutations reported for conjunctival melanomas and chromosome changes less 258 
frequent in UM, but sometime reported for conjunctival melanoma.   259 
 260 
 261 
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Gene Exon Forward Primer Sequence 5′-3′ Reverse Primer Sequence 5′-3′ Reference 
GNAQ 5 AGAAGTAAGTTCACTCCATTCCC TTCCCTAAGTTTGTAAGTAGTGC 5 
GNAQ 4 TCTTTTTCTCCCACCCCTTGC TTGTTTTGAAGCCTACACATGATTCC 6 
GNA11 5 CGCTGTGTCCTTTCAGGATG CCTCGTTGTCCGACT 5 
GNA11 4 GTGCTGTGTCCCTGTCCTG GGCAAATGAGCCTCTCAGTG 6 
BRAF 15 TCATAATGCTTGCTCTGATAGGA GGCCAAAAATTTAATCAG 5 
NRAS 2 CGGTGTTTTTGCGTTCTCTAGTC TCCGACAAGTGAGAGACAGGAT 9 
NRAS 3 TTGAGGGACAAACCAGATAGGC CCTTCGCCTGTC TCATGTATT 9 
SF3B1 15 TGATTATGGAAAGAAATGGTTGAAG 
 
CATGTTCAATGATTTCAACTAAACTTC 
 
8 
EIF1AX 1 GAAAAGCGACGCAAAGAGTC 
 
CTGGGTGACCTGCAATCTAC 
 
8 
TERT promoter GTCCTGCCCCTTCACCTT GCTTCCCACGTGCGCA 10 
 
Table 1. Primer sequences used in study  
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Case Sex Laterality Presentation Radiology Post 
biopsy 
treatment 
Post surgical 
treatment 
Clinical course 
1 M L Reduced VA and pain 
2/52; 4 mm proptosis and 
slight upward globe 
displacement. RAPD 
MRI: Posterior 22mm MD left 
fusiform mass abutting medial 
rectus with compression of optic 
nerve.  Body PET-clear. 
SSOE Post-op orbital 
radiotherapy 
No local recurrence. Miliary type 
liver metastases and epigastric 
lymphadenopathy 24 months 
after orbit surgery. Died 36 
months after orbital diagnosis 
2 M R Puffiness around R eye; 
inferotemporal 6mm 
proptosis 
MRI-Equatorial 44mm MD 
supero-nasal mass above 
superior and medial rectus. No 
extrorbital spread. Body PET-
clear 
SSOE Post-op orbital 
radiotherapy 
No local recurrence and no 
metastases to date. Well and 
alive.60 months post-surgery   
3 F L Left proptosis and left sub 
conjunctival haemorrhage 
VA 6/6 ; left 6th nerve 
palsy 
MRI: Posterior 26mm MD well-
defined mass around lateral 
rectus and adjacent to lacrimal 
gland. Body PET-all clear. 
SSOE Post-op orbital 
radiotherapy 
No local recurrence and no 
metastases to date. Well and 
alive 36 months post-surgery. 
4 F L 3/12 proptosis CT-extensive homogeneous 
orbital mass and multiple liver 
and bone metastases 
nil No treatment. 
Systemic 
palliative 
support. 
Died 8 weeks after orbital biopsy 
from multiple bone and liver 
metastases. 
5 M L Painless loss of vision; 
RAPD,  proptosis; 
restricted eye movements 
CT and MRI- left fusiform mass 
abutting medial rectus mass. CT 
whole body-no masses 
nil No treatment. 
Systemic 
palliative 
support 
Died 6 weeks after orbital biopsy 
from cerebral metastases. 
6 M R Supero-temporal mass. 
Diplopia on R gaze 
CT- Anterior 26mm MD supero-
lateral ovoid mass overlying 
insertions of superior rectus, 
superior oblique and lateral 
rectus. Separate from lacrimal 
gland. CT whole body-all clear 
SSOE No local 
treatment 
No local recurrence and no 
metastases. Died of unrelated 
causes 48 months post-surgery.   
 
Table 2 Summary of clinical and radiological features of the 6 cases 
M (male); L(left); R(right); VA (visual acuity); RAPD (relative afferent pupillary defect; MD (maximum dimension); SSOE (Skin sparing orbital exenteration) 
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Case 
number 
histology Melanocytosis?  BAP1 
immunohistochemistry  
case 1 Exenteration: Posterior melanoma invading EOM; Central Nec with 
melanophages; mostly Sp cells & some Ep cells. No LVS; No PN ; 
HMB45+ MelanA+ Sox10+. No conjunctival or uveal melanoma.  
Yes-melanocytosis of choroid, sclera, 
episclera and orbit soft tissue.  
Absent nuclear 
expression 
case 2 Exenteration: Superior equatorial melanoma; Sp &E cells; packeted 
architecture; vascular invasion; No PN; Melan A+HMB45+ Sox10+. 
No conjunctival or uveal melanoma. 
Yes-scattered benign spindle cells in 
orbit soft tissue around melanoma.  
nuclear expression 
case 3 Exenteration: Posterior orbital melanoma; Sp cells; Nec; No LVS; No 
PN; Melan A+, HMB45+ Sox10+; 
No conjunctival or uveal melanoma. 
Yes-scattered benign spindle cells in 
orbit soft tissue adjacent and distant 
from melanoma 
nuclear expression 
case 4 Incisional biopsy (taken from anterior orbit): Melanoma; Sp &Ep cells 
with focal balloon cell change; packeted architecture. Melan A+, 
HMB45+, Sox10+  
Not assessable histologically  nuclear expression 
case 5 Incisional biopsy (taken from anterior medial orbit) : Melanoma; Sp 
&Ep cells Melan A, HMB45 Sox10+  
Not assessable histologically  nuclear expression 
case 6 Exenteration: Anterior orbital melanoma; Ep cell rich; balloon cell 
change; No LVS; No PN; Melan A+HMB45+; Sox10+; No 
conjunctival or uveal melanoma.  
No  nuclear expression 
 
Table 3 Summary of the histological findings.  
Key: EOM-extraocular muscle; Nec-necrosis; Sp-spindle; Ep-epithelioid; LVS-lymphovascular space invasion; PN-
perineural invasion;  
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case no. 
   GNAQ GNA11 SF3B1 EIF1AX BRAF NRAS TERT gain of chromosomal copy number loss of chromosomal copy number  
1               8q (partial) 3, 1p (partial) 
2               6, 8q, 9, 10, 11, 13, 17, 21 19 
3               1p (focal), 6p (partial), 17q(partial), 20q (focal)  1p (partial), 4q (partial), 8p (partial), 9p (partial) 
4               6p (partial), 7p (focal), 8 none 
5               1p (partial), 6, 13q (partial), 17q, 20p (focal)  16p (focal), 16q (partial), 17p, 20q (focal) 
6               6p, 17q, 20p (focal) 9 (focal), 10, 16 (partial), 17p, 20q (focal), 21  
 * focal losses and gains not reported in table were identified as CNVs due to unmatched control DNA used for aCGH  
 
** where wildtype reported for GNAQ, GNA11 and NRAS, indicates wildtype for all mutational sites analysed as outlined in table 1 
 
  SF3B1 (R625) 
 
  GNAQ (R183) 
 
  GNA11 (Q209) 
 
  NRAS (G12) 
 
  TERT (p.146) 
 
  wildtype 
 
  failed 
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Highlights 
 
The study presents the genetic profiles of 6 primary orbital melanomas. The data 
suggests there are 2 subgroups: A uveal-like signature and a conjunctival-like 
signature, with the uveal-like group possibly associated with benign precursors.  
 
